Every material Form 8-K Roivant Sciences filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Roivant reported results for the quarter ended September 30, 2024, with a net loss attributable to the company of $230.2 million, or $0.31 per share, compared with $304.3 million, or $0.40 per share, a year earlier. Net revenue rose to $4.5 million from $3.6 million, but general and administrative expenses rose to $202.9 million, including $79.1 million of one-time cash retention awards, and the non-GAAP loss from continuing operations widened to $218.7 million from $154.8 million.
Net loss attributable to Roivant was $230.2 million ($0.31 per share) vs. $304.3 million ($0.40 per share) a year earlier.
Revenue, net was $4.5 million vs. $3.6 million; R&D expenses were $143.1 million vs. $114.8 million.
G&A expenses were $202.9 million vs. $88.6 million, including $79.1 million of one-time cash retention awards approved in July 2024.
Cash, cash equivalents and marketable securities were approximately $5.4 billion at September 30, 2024, after $106 million of share repurchases in the quarter.
Roivant's subsidiary Dermavant agreed on September 17, 2024 to be acquired by Organon for up to about $1.2 billion, including a $175 million payment at closing, a $75 million milestone on FDA approval of VTAMA for atopic dermatitis, and up to $950 million in sales-based milestones, plus tiered royalties. Roivant owns about 87% of Dermavant's shares, so the deal would deliver most of the proceeds to Roivant, though the amount depends on future milestones and the closing is subject to conditions.
Organon agreed to acquire Dermavant for up to about $1.2 billion in aggregate cash consideration, including a $175 million payment at closing
Additional $75 million payable on FDA approval of VTAMA for atopic dermatitis, and up to $950 million in tiered net sales milestones
Roivant owns approximately 87% of Dermavant's common and preference shares; shareholder written consent of at least 75% of voting rights was obtained
Expected to close in the fourth quarter of 2024; either party may terminate if not closed by March 17, 2025
Roivant reported results for the fiscal quarter ended June 30, 2024, with revenue of $55.1 million, up from $21.6 million a year earlier, and net income of $57.5 million compared with a net loss of $327.8 million. The profit includes a $110.4 million gain on the sale of Telavant net assets, and the company's non-GAAP net loss was $131.2 million, narrower than $211.5 million a year earlier.
Revenue, net was $55.1 million versus $21.6 million a year earlier; product revenue, net was $18.4 million
Net income was $57.5 million, or $0.13 basic and $0.12 diluted per share, versus a net loss of $0.38 per share a year earlier
Gain on sale of Telavant net assets of $110.4 million; non-GAAP net loss was $131.2 million versus $211.5 million
Cash, cash equivalents and restricted cash were approximately $5.7 billion at June 30, 2024, after a $648 million share repurchase announced in April 2024
On May 24, 2024, Roivant subsidiary Dermavant Sciences Ltd. entered into agreements to renegotiate its debt, which the filing says would reduce potential cash payments by over $300 million in aggregate. Roivant will contribute $195 million in preferred equity to Dermavant, and the royalty purchasers and NovaQuest receive about 13.2% of Dermavant's shares, leaving Roivant with about 87% of common and preferred shares after closing. For shareholders, the deal lowers future cash obligations but dilutes Roivant's stake in Dermavant and raises the interest rate on one credit agreement.
Debt Renegotiation expected to reduce potential cash payments by over $300 million in aggregate, with about $225 million achieved over the next three fiscal years.
Roivant to contribute $195 million to Dermavant for convertible preferred shares with a liquidation preference of 1.5 times invested capital.
Credit Agreement maturity extended from May 2026 to May 2028, with the interest rate rising from 10% to 12.25% per annum.
NovaQuest eliminates fixed quarterly payments totaling $176.3 million and milestone payments of up to $141.0 million; remaining payments of $122.5 million run through March 31, 2029.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Roivant Sciences filing is on SEC EDGAR ↗. 8-K briefs of other companies →